Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Pemetrexed Market- Insights
Pemetrexed, sold under brand name Alimta by Eli Lilly and Company is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. In February 2004, Eli Lilly and Company received U.S. Food and Drug Administration approval for pemetrexed for treatment of malignant pleural mesothelioma, and in 2008, company received another approval from FDA for treatment of advanced and metastatic non-small cell lung cancer.
Alimta is a folate analog metabolic inhibitor and in combinations with certain drugs it is indicated for various diseases:
- In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC)
- As a single agent for the maintenance and treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC), whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
- As a single agent for the treatment of patients with recurrent metastatic nonsquamous non-small cell lung cancer (NSCLC) after prior chemotherapy
- In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma (MPM) whose disease is unresectable or who are otherwise not candidates for curative surgery
Approval and Launch of Affordable Generic of Pemetrexed in Market is Expected to Increase its Adoption
Alimta is a patented drug of Eli Lilly and Company and is protected by a vitamin regimen patent (2021), and pediatric exclusivity (2022) in the U.S., vitamin regimen patent (2021) in major European countries, and patents covering use to treat cancer concomitantly with vitamins (2021) in the Japan.
However, Eli Lilly and Company’s compound patent for Alimta expired in the U.S. in January 2017, and expired in major European countries and Japan in December 2015.
Various other key players have gained regulatory approval for the generic versions of pemetrexed and are expected to launch during the forecast period. Launch of generic version at low price is expected to rise adoption of the drug, which in turn will drive pemetrexed market growth over forecast period.
For instance, in July 2018, the German Federal Patent Court declared the German section of European patent EP 1 313 508 for Alimta, void. Following this, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.
Furthermore, Eli Lilly and Company is dedicated in frequent research and development in order to expand the indication of Alimta and to generate high revenue benefits.
For instance, in June 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.
Approval of novel indications of pemetrexed is expected to support and drive global pemetrexed market growth over the forecast period.
The global pemetrexed market size was valued at US$ 2062.5 Mn in 2017 and is expected to witness a CAGR of 1.3% during the forecast period (2018 – 2026).
North America is expected to Hold Dominant Position, Owing to High Prevalence of Non-small Cell Lung Cancer and its High Treatment Rate in the U.S.
According to Eli Lilly and Company’s annual report 2017, Alimta (pemetrexed) generated around 50% of its revenue from the U.S. Hence, North America is expected to be most conducive region for growth of the pemetrexed market, due to high prevalence of non-small cell lung cancer and high cost for its treatment.
For instance, according to the data published by the American Cancer Society in 2017, lung cancer (both small cell and non-small cell) is the second most common type of cancer in U.S and around 13% of all new cancers are lung cancer.
American Cancer Society also estimated that in 2019, around 228,150 new cases of lung cancer (116,440 in men and 111,710 in women) would be diagnosed in the U.S. and survival rate for non-small cell lung cancer in stage IA1 NSCLC is about 92%, stage IB NSCLC (68%), stage IIIA NSCLC (36%), stage IIIC cancers (13%), and for stage IIIC cancers (13%).
Figure 1. Alimta Revenue (%) Analysis, By Region, 2017
Source: Eli Lilly and Company Annual Report (2019)
Figure 2. Global Pemetrexed Market Share (%) Analysis, By Region, 2018
Source: Coherent Market Insights Analysis (2019)
Key players operating in the global pemetrexed market include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others.